The stock of Cue Biopharma Inc (CUE) has seen a -24.71% decrease in the past week, with a -37.50% drop in the past month, and a -27.88% decrease in the past quarter. The volatility ratio for the week is 11.72%, and the volatility levels for the past 30 days are at 9.82% for CUE. The simple moving average for the past 20 days is -23.98% for CUE’s stock, with a -30.73% simple moving average for the past 200 days.
Is It Worth Investing in Cue Biopharma Inc (NASDAQ: CUE) Right Now?
CUE has 36-month beta value of 2.03. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CUE is 62.87M, and currently, short sellers hold a 1.37% ratio of that float. The average trading volume of CUE on April 02, 2025 was 239.91K shares.
CUE) stock’s latest price update
The stock price of Cue Biopharma Inc (NASDAQ: CUE) has dropped by -17.67 compared to previous close of 0.91. Despite this, the company has seen a fall of -24.71% in its stock price over the last five trading days. zacks.com reported 2025-03-31 that Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.
Analysts’ Opinion of CUE
Many brokerage firms have already submitted their reports for CUE stocks, with Jefferies repeating the rating for CUE by listing it as a “Buy.” The predicted price for CUE in the upcoming period, according to Jefferies is $6 based on the research report published on March 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CUE reach a price target of $10. The rating they have provided for CUE stocks is “Outperform” according to the report published on June 26th, 2023.
Piper Sandler gave a rating of “Overweight” to CUE, setting the target price at $7 in the report published on November 21st of the previous year.
CUE Trading at -37.27% from the 50-Day Moving Average
After a stumble in the market that brought CUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.81% of loss for the given period.
Volatility was left at 9.82%, however, over the last 30 days, the volatility rate increased by 11.72%, as shares sank -35.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.75% lower at present.
During the last 5 trading sessions, CUE fell by -24.71%, which changed the moving average for the period of 200-days by -50.00% in comparison to the 20-day moving average, which settled at $0.9866. In addition, Cue Biopharma Inc saw -31.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CUE starting from PASSERI DANIEL R, who purchase 30,000 shares at the price of $1.03 back on Dec 16 ’24. After this action, PASSERI DANIEL R now owns 164,578 shares of Cue Biopharma Inc, valued at $30,900 using the latest closing price.
Stock Fundamentals for CUE
Current profitability levels for the company are sitting at:
- -4.78 for the present operating margin
- -0.18 for the gross margin
The net margin for Cue Biopharma Inc stands at -4.68. The total capital return value is set at -1.63. Equity return is now at value -149.03, with -86.80 for asset returns.
Based on Cue Biopharma Inc (CUE), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -4.02. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -39.57.
Currently, EBITDA for the company is -41.5 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 2.58. The receivables turnover for the company is 3.02for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To put it simply, Cue Biopharma Inc (CUE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
